{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:06:25Z","timestamp":1787911585333,"version":"build-2784847793"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has proven effective for treating relapsed or refractory acute B cell leukemia. However, challenges such as cytokine release syndrome, T cell dysfunction, and exhaustion persist. Enhancing CAR-T cell efficacy through changing CAR internalization and recycling is a promising approach. The transmembrane domain is the easiest motif to optimize for modulating CAR internalization and recycling without introducing additional domains, and its impact on CAR internalization and recycling has not yet been thoroughly explored. In this study, we aim to enhance CAR-T cell function by focusing on the solely transmembrane domain design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Utilizing plasmid construction and lentivirus generation, we get two different transmembrane CAR-T cells [19CAR-T(1a) and 19CAR-T(8\u03b1)]. Through co-culture with tumor cells, we evaluate CAR dynamic change, activation levels, exhaustion markers, mitochondrial function, and differentiation in both CAR-T cells. Furthermore, immunofluorescence microscopy analysis is performed to reveal the localization of internalized CAR molecules. RNA sequencing is used to detect the transcriptome of activated CAR-T cells. Finally, a mouse study is utilized to verify the anti-tumor efficacy of 19CAR-T(1a) cells\n                      <jats:italic>in vivo<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our findings demonstrate that 19CAR-T(1a) has lower surface CAR expression, faster internalization, and a higher recycling rate compared to 19CAR-T(8\u03b1). Internalized 19CAR(1a) co-localizes more with early and recycling endosomes, and less with lysosomes than 19CAR(8\u03b1). These features result in lower activation levels, less cytokine release, and reduced exhaustion markers in 19CAR-T(1a). Furthermore, CAR-T cells with CD1a transmembrane domain also exhibit a superior anti-tumor ability and reduced exhaustion\n                      <jats:italic>in vivo<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, we demonstrate that the transmembrane domain plays a critical role in CAR-T cell function. An optimized transmembrane domain can alleviate cytokine release syndrome and reduce CAR-T cell exhaustion, providing a direction for CAR design to enhance CAR-T cell function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1531344","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T19:54:47Z","timestamp":1743105287000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Improved CAR internalization and recycling through transmembrane domain optimization reduces CAR-T cytokine release and exhaustion"],"prefix":"10.3389","volume":"16","author":[{"given":"Shufeng","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajian","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyu","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenshu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e247065","DOI":"10.6004\/jnccn.2024.7065","article-title":"The role of CAR T-cell therapy in relapsed\/refractory adult B-ALL","volume":"22","author":"Othman","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795164","article-title":"Recent advances in solid tumor CAR-T cell therapy: driving tumor cells from hero to zero","volume":"13","author":"Safarzadeh Kozani","year":"2022","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic Malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.05.007","article-title":"Future perspectives on engineered T cells for cancer","volume":"10","author":"Posey","year":"2024","journal-title":"Trends Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01896-9","article-title":"T cell dysfunction and therapeutic intervention in cancer","volume":"25","author":"Zebley","year":"2024","journal-title":"Nat Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo0514","article-title":"CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome","volume":"8","author":"Rodriguez-Marquez","year":"2022","journal-title":"Sci Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.03.007","article-title":"Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo","volume":"21","author":"Ho","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01571-5","article-title":"CTLA-4 tail fusion enhances CAR-T antitumor immunity","volume":"24","author":"Zhou","year":"2023","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.immuni.2020.07.011","article-title":"Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy","volume":"53","author":"Li","year":"2020","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.639818","article-title":"The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28","volume":"12","author":"Muller","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901766","article-title":"The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1016\/j.cell.2023.08.022","article-title":"CD1 lipidomes reveal lipid-binding motifs and size-based antigen-display mechanisms","volume":"186","author":"Huang","year":"2023","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.073031","article-title":"Transmembrane domains control exclusion of membrane proteins from clathrin-coated pits","volume":"123","author":"Mercanti","year":"2010","journal-title":"J Cell Sci"},{"key":"B20","article-title":"Treatment of cancer using humanized anti-CD19 chimeric antigen receptor","author":"Brogdon","year":"2014","journal-title":"US Patent App"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumor antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7150\/thno.66832","article-title":"A T-cell independent universal cellular therapy strategy through antigen depletion","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2001.01264.x","article-title":"CD1a molecules traffic through the early recycling endosomal pathway in human Langerhans cells","volume":"116","author":"Salamero","year":"2001","journal-title":"J Invest Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0804140","article-title":"Early recycling compartment trafficking of CD1a is essential for its intersection and presentation of lipid antigens","volume":"184","author":"Cernadas","year":"2010","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"102177","DOI":"10.1016\/j.ceb.2023.102177","article-title":"Insights into the role of the membranes in Rab GTPase regulation","volume":"83","author":"Wilmes","year":"2023","journal-title":"Curr Opin Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"139828","DOI":"10.1016\/j.ijbiomac.2025.139828","article-title":"A review on evolution, structural characteristics, interactions, and regulation of the membrane transport protein: The family of Rab proteins","volume":"296","author":"Parray","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/imcb.v101.6","article-title":"T-cell activation-induced marker assays in health and disease","volume":"101","author":"Poloni","year":"2023","journal-title":"Immunol Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1104771","article-title":"T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications","volume":"14","author":"Chi","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1038\/s41467-024-46377-7","article-title":"Mitochondrial metabolism sustains CD8(+) T cell migration for an efficient infiltration into solid tumors","volume":"15","author":"Simula","year":"2024","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3390\/cancers13061229","article-title":"Metabolic and mitochondrial functioning in chimeric antigen receptor (CAR)-T cells","volume":"13","author":"Rad","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"109911","DOI":"10.1016\/j.celrep.2021.109911","article-title":"Regulatory T cell differentiation is controlled by \u03b1KG-induced alterations in mitochondrial metabolism and lipid homeostasis","volume":"37","author":"Matias","year":"2021","journal-title":"Cell Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.immuni.2017.02.010","article-title":"Integrative proteomics and phosphoproteomics profiling reveals dynamic signaling networks and bioenergetics pathways underlying T cell activation","volume":"46","author":"Tan","year":"2017","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02257-z","article-title":"Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose","volume":"38","author":"Gross","year":"2024","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci Transl Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discovery"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e75660","DOI":"10.7554\/eLife.75660","article-title":"De novo-designed transmembrane domains tune engineered receptor functions","volume":"11","author":"Elazar","year":"2022","journal-title":"Elife"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1531344\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T19:54:50Z","timestamp":1743105290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1531344\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2025.1531344"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1531344","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"article-number":"1531344"}}